These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38362827)

  • 1. Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.
    Sawant-Basak A; Bergman AJ; Mancuso J; Tripathy S; Gosset JR; Mendes da Costa L; Esler WP; Calle RA
    Clin Transl Sci; 2024 Feb; 17(2):e13687. PubMed ID: 38362827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
    Amin NB; Saxena AR; Somayaji V; Dullea R
    Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
    Futatsugi K; Cabral S; Kung DW; Huard K; Lee E; Boehm M; Bauman J; Clark RW; Coffey SB; Crowley C; Dechert-Schmitt AM; Dowling MS; Dullea R; Gosset JR; Kalgutkar AS; Kou K; Li Q; Lian Y; Loria PM; Londregan AT; Niosi M; Orozco C; Pettersen JC; Pfefferkorn JA; Polivkova J; Ross TT; Sharma R; Stock IA; Tesz G; Wisniewska H; Goodwin B; Price DA
    J Med Chem; 2022 Nov; 65(22):15000-15013. PubMed ID: 36322383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
    Amin NB; Darekar A; Anstee QM; Wong VW; Tacke F; Vourvahis M; Lee DS; Charlton M; Alkhouri N; Nakajima A; Yunis C
    BMJ Open; 2022 Mar; 12(3):e056159. PubMed ID: 35354614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
    Calle RA; Amin NB; Carvajal-Gonzalez S; Ross TT; Bergman A; Aggarwal S; Crowley C; Rinaldi A; Mancuso J; Aggarwal N; Somayaji V; Inglot M; Tuthill TA; Kou K; Boucher M; Tesz G; Dullea R; Bence KK; Kim AM; Pfefferkorn JA; Esler WP
    Nat Med; 2021 Oct; 27(10):1836-1848. PubMed ID: 34635855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans.
    Ryder TF; Bergman A; King-Ahmad A; Amin NB; Lall MS; Ballard TE; Kalgutkar AS
    Xenobiotica; 2022 Mar; 52(3):240-253. PubMed ID: 35382680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
    Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
    Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
    Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
    Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
    Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
    Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
    Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
    Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
    Amin NB; Carvajal-Gonzalez S; Purkal J; Zhu T; Crowley C; Perez S; Chidsey K; Kim AM; Goodwin B
    Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
    Li J; Kankam M; Trone D; Gammon G
    Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
    Shaik MN; LaBadie RR; Rudin D; Levin WJ
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Postnatal Resolution of Developmental Toxicity Induced by Pharmacological Diacylglycerol Acyltransferase 2 (DGAT2) Inhibition During Gestation in Rats.
    Catlin NR; Bowman CJ; Campion SN; Lewis EM; Nowland WS; Stethem C; Cappon GD
    Toxicol Sci; 2022 Sep; 189(2):225-236. PubMed ID: 35866640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
    Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
    Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.